The Royal Marsden in Sutton, Surrey
Welcome,         Profile    Billing    Logout  
 0 Trials 
10 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Harrison, Rebecca
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
Cher, Lawrence
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
Lwin, Zarnie
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
TCaP, NCT06157541: T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

Recruiting
1/2
58
RoW
Allogeneic cytomegalovirus-specific T cells, CYT-101, Pembrolizumab, Keytruda
Queensland Institute of Medical Research, CUREator, Merck Sharp & Dohme LLC, The Newro Foundation, Royal Brisbane and Women's Hospital, Princess Alexandra Hospital, Brisbane, Australia, Austin Hospital, Melbourne Australia
Glioblastoma Multiforme, Astrocytoma, Grade IV
04/26
01/28
Heath, John
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
Valvi, Santosh
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
NCT06161974: Study of Olutasidenib and Temozolomide in HGG

Not yet recruiting
2
60
Europe, Canada, US, RoW
Olutasidenib + TMZ
Rigel Pharmaceuticals, Nationwide Children's Hospital
High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
06/29
06/35
Carceller, Fernando
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
Bergmeister-Berghoff, Anna
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26

Download Options